Showing results (1381-1390 of 10,079) with videos related to
Sort By:
Pageof 1,008
Current Pharmaceutical Design|April 12, 2002
Gastrointestinal safety of selective COX-2 inhibitorsC J Hawkey, M M SkellyCurrent Pharmaceutical Design|April 12, 2002
Trypsin and chymotrypsin inhibitors in insects and gut leechesLiliane Schoofs, Elke Clynen, Michel SalzetCurrent Pharmaceutical Design|April 12, 2002
The role of protease inhibition with emphasis on the effects of inflammation and vascular immune phenomenaT V Bilfinger, George B StefanoCurrent Pharmaceutical Design|April 12, 2002
Fatty acid amide hydrolase, an enzyme with many bioactive substrates. Possible therapeutic implicationsTiziana Bisogno, Luciano De Petrocellis, Vincenzo Di MarzoCurrent Pharmaceutical Design|April 12, 2002
Tailoring an antibacterial peptide of human lysosomal cathepsin G to enhance its broad-spectrum action against antibiotic-resistant bacterial pathogensW M Shafer, S Katzif, S Bowers, et al.Current Pharmaceutical Design|October 29, 2009
Prediction of MHC-peptide binding: a systematic and comprehensive overviewEsther M Lafuente, Pedro A RecheCurrent Pharmaceutical Design|October 29, 2009
HLA-DR: molecular insights and vaccine designLawrence J Stern, J Mauricio Calvo-CalleCurrent Pharmaceutical Design|October 29, 2009
Vascular damage in impaired glucose tolerance: an unappreciated phenomenon?Shahirose Jessani, Teri Millane, Gregory Y H LipCurrent Pharmaceutical Design|October 29, 2009
Drug combinations for dyslipidemia and obesity treatment in metabolic syndromeM Florentin, M S Elisaf, D P Mikhailidis, et al.Current Pharmaceutical Design|October 29, 2009
Phosphodiesterase type 5 inhibitors: unmet needsK Hatzimouratidis, D G HatzichristouPageof 1,008